Publications by authors named "S SCHULMAN"

Article Synopsis
  • Recent developments have improved our understanding of the molecular processes that lead to thrombus formation, particularly regarding deep vein thrombosis (DVT), which can be triggered by various factors like trauma, immobility, or genetic issues.
  • About half of DVT cases are unprovoked, involving mechanisms such as venous stasis and hypoxia, raising the importance of immunothrombosis, especially during conditions like COVID-19 that exacerbate inflammation and promote microthrombi formation.
  • Research involving animal models and clinical studies has revealed the intricate relationship between immune cells, blood components, and various factors influencing coagulation, providing a deeper insight into the causes of hypercoagulability and venous thromboembolism.
View Article and Find Full Text PDF

Background: The Multicenter Evaluation of the Duration of Therapy for Thrombosis in Children multinational, randomized clinical trial revealed noninferiority of a 6-week vs 3-month duration of anticoagulation for the treatment of provoked venous thromboembolism (VTE) in patients <21 years old in regard to net clinical benefit at 1 year.

Objectives: To evaluate noninferiority at 2 years.

Methods: Patients whose repeat imaging 6 weeks after VTE diagnosis did not show complete veno-occlusion were randomized to discontinue anticoagulation vs receive a total 3-month course and followed for 2 years for the occurrence of symptomatic recurrent VTE (efficacy outcome) and clinically relevant bleeding (safety outcome).

View Article and Find Full Text PDF

Introduction: Factor Xa inhibitor (FXaI)-associated bleeding events are common and associated with substantial morbidity. Systematic evaluation of widely available, effective, and affordable FXaI bleed management strategies is needed.

Materials And Methods: We conducted a single-center retrospective cohort study of FXaI-treated patients presenting to a tertiary academic medical center from January 2018 to May 2019 who received 25-50 IU/kg 4F-PCC for either FXaI-associated major bleeding or urgent surgery.

View Article and Find Full Text PDF
Article Synopsis
  • * Follow-up showed that most positive aPL were transient or low titer, while 10% met criteria for antiphospholipid syndrome (APS), which was linked to a significantly higher risk of recurrent VTE.
  • * The research highlights the need for further studies on managing VTE in children, particularly for those diagnosed with APS, given their higher recurrence risk.
View Article and Find Full Text PDF